This clinical trial tests how well Num vapocoolant works to prevent the pain associated with lymphoscintigraphy. Lymphoscintigraphy is a method used to check for sentinel lymph nodes using a radioactive substance that is injected into the body and taken up by the lymph nodes. A scanner is then used to visualize the lymph nodes. The injection of the radioactive substance is often described as painful and can cause anxiety because the procedure usually does not involve any form of anesthesia or numbing medications. Num is a spray that cools and numbs the skin (vapocoolant) to control pain during minor surgical procedures including injections. Giving Num vapocoolant prior to the lymphoscintigraphy injection may prevent pain and reduce the anxiety associated with the injections.
Additional locations may be listed on ClinicalTrials.gov for NCT05744557.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVES:
I. Establish feasibility of topical vapocoolant in the setting of breast lymphoscintigraphy.
II. Demonstrate safety of topical vapocoolant in the setting of breast lymphoscintigraphy.
SECONDARY OBJECTIVES:
I. To assess patient pain intensity associated with the performance of breast lymphoscintigraphy.
II. To evaluate the attitude from patients about supporting the continued offering of topical vapocoolant in the breast lymphoscintigraphy clinic.
OUTLINE:
Patients receive Num vapocoolant topically to injection site and receive Tc-99m macroaggregated albumin injection or Tc-99m tilmanocept injection and then undergo breast lymphoscintigraphy scan on study.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationM D Anderson Cancer Center
Principal InvestigatorSanjit O. Tewari
